Biopharmaceutical company Kamada has been granted an orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for its Alpha-1 Antitrypsin (AAT) drug to treat type 1 diabetes.

The company is currently undergoing a Phase I/II clinical trial with AAT by IV route of administration.

AAT IV was granted FDA approval in July 2010 for the treatment of Alpha 1 deficiency and is exclusively marketed by Baxter in the US.

Kamada’s next-generation AAT by inhalation is currently undergoing a Phase 2-3 trial in Europe.

The company has already completed five clinical trials with its high purity, liquid formulation of inhaled Alpha-1 Antitrypsin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData